Media

We might like experiencing new places, but our tummies don’t always agree with us. Here’s something that might suit some. Travelan is an immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®

Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream.

Host Jonathan Miller interviews CEO: Steven Lydeamore. He talks about the exponential growth on sales in the past year.

Planet MicroCap spoke with Steven Lydeamore, CEO of Immuron Ltd. (ASX: IMC) (NASDAQ: IMRN) via Zoom to discuss

Immuron Limited (ASX: IMC; NASDAQ: IMRN), the Melbourne-based biopharmaceutical firm, has reported a stellar performance for FY23 with a 136% surge in global sales compared to FY22.

The Board of Directors of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has given the green light for the company to proceed with IMM-529 cGMP manufacturing for the treatment of a form of gastrointestinal disease.

Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore is a numbers guy. You can tell by the thoughtful, considered way he reflects on his experience that a knack for numbers has informed his leadership style.

Immuron Ltd posted a revenue of $584,000 in H1 FY23, a growth of 153% compared to H1 FY22, with Australian sales contributing $287,000.

Immuron Limited CEO Steven Lydeamore interview with Stuart Roberts Management Interview Series – Stocks Down Under

Immuron (ASX:IMC) has updated on the US Department of Defense Uniformed Services University (USU) clinical evaluation of the company's Travelan.

Immuron Limited CEO Steven Lydeamore joined Steve Darling from Proactive to share news about the Australian Biotech company that is looking at using its technology for product development around gut health

Immuron (ASX:IMC) CEO Steven Lydeamore presents at The Capital Network's Emerging ASX Gems investment conference on Friday 4 November 2022.

Immuron (IMC) listed as a company to watch in the recent Stockhead investor guide.

Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates.

Biopharmaceutical company Immuron (IMC) has seen a 494 per cent increase in North American Travelan sales for FY22.

Immuron (IMC) has entered a research agreement with Monash University to evaluate the efficacy of IMM-124E and advance SARS-CoV-2 findings.

Immuron’s (IMC) share price has more than doubled on the news a drug used in its traveller’s diarrhoea formulation neutralises activity aginst the COVID-19 virus.

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors.